Kayexalate · DIN 02026961 · 1mEq/g · Oral Pd-454g Pk
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Kayexalate · DIN 02026961
Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01
Health Canada: Marketed since 2009-02-06 · brand KAYEXALATE · ATC V03AE01 POLYSTYRENE SULPHONATE · form Powder for suspension · route Oral, Rectal · ingredients SODIUM POLYSTYRENE SULFONATE 1 G/G · company Sanofi-aventis canada inc · schedule Prescription
Ministry pays: $29.4175 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02026961)
Source record
DIN 02026961: Kayexalate
Raw flags: sec3=Y
Item: 401800001; group id 551; item number 1487; lccId None; manufacturer id SAV
Source form: Oral Pd-454g Pk; strength: 1mEq/g
Recorded listing: General benefit
Source prices (unrounded): $43.6300; ministry $29.4175
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02026961
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17752
Interchangeable products
Jamp Sodium Polystyrene Sulfonate · DIN 02497557 · $29.4175
Odan-Sodium Polystyrene Sulfonate · DIN 02473941 · $29.4175
Solystat · DIN 00755338 · $29.4175
Shortage status: not checked (no credentials)